Document

SC 13G 1 dva-formsc13grockwellmedic.htm SC 13G Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Rockwell Medical, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

774374102

(CUSIP Number)

April 6, 2022

(Date of Event Which Requires Filing of this Statement)

Check the Appropriate Box to Designate the Rule Pursuant to Which this Schedule Is Filed:

☐

Rule 13d-1(b)

☑

Rule 13d-1(c)

☐

Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Continued on following pages

Page 1 of 6 Pages

SCHEDULE 13G

CUSIP: 774374102 Page 2 of 6 Pages



1.	Names of Reporting Persons DaVita Inc.
2.	Check The Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned By Each Reporting Person With		5.	Sole Voting Power 7,500,000*
		6.	Shared Voting Power 0
		7.	Sole Dispositive Power 7,500,000*
		8.	Shared Dispositive Power 0
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 7,500,000*
10.	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares ☐
11.	Percent of Class Represented By Amount in Row (9) 7.4%*
12.	Type of Reporting Person (See Instructions) CO, HC

* See Item 4.

SCHEDULE 13G

CUSIP: 774374102 Page 3 of 6 Pages

Item 1(a)

Name of Issuer

Rockwell Medical, Inc. (the “Issuer”)

Item 1(b)

Address of the Issuer’s Principal Executive Offices

30142 S. Wixom Road

Wixom, MI 48393

Item 2(a)

Names of Persons Filing

DaVita Inc. (the “Reporting Person”)

Item 2(b)

Address of the Principal Business Office, or if none, Residence

2000 16th Street

Denver, CO 80202

Item 2(c)

Citizenship

Delaware

Item 2(d)

Title of Class of Securities

Common Stock, par value $0.0001 per share (“Common Stock”)

Item 2(e)

CUSIP Number

774374102

Item 3

If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

Not Applicable

Item 4

Ownership

SCHEDULE 13G

CUSIP: 774374102 Page 4 of 6 Pages

Item 4(a)

Amount Beneficially Owned:

As of the date hereof, the Reporting Person may be deemed the beneficial owner of 7,500,000 shares of Common Stock that the Reporting Person has the right to acquire upon conversion of shares of Series X Convertible Preferred Stock, par value $0.0001 per share, of the Corporation (the “Series X Preferred Stock”).

On April 6, 2022, the Reporting Person entered into a Securities Purchase Agreement with the Issuer pursuant to which the Reporting Person (i) purchased 7,500 shares of Series X Preferred Stock at a price of $1,000 per share, and (ii) agreed to purchase an additional 7,500 shares of Series X Preferred Stock at a price of $1,000 per share if the Issuer raises additional capital by an outside date (the “Second Tranche”). The Series X Preferred Stock has an initial conversion rate of 1,000 shares of Common Stock per share of Series X Preferred Stock, subject to adjustment as set forth in the Certificate of Designation. However, the Certificate of Designation for the Series X Preferred Stock provides that the Reporting Person shall not have the right to convert any portion of the Series X Preferred Stock to the extent that, after giving effect to an attempted conversion, the Reporting Person, together with its affiliates and any persons acting as a “group” with the Reporting Person, exceeds 9.9% (the “Blocker”). Accordingly, to the extent the Second Tranche is issued, the amount of shares of Common Stock that the Reporting Person has the right to acquire upon conversion of the Series X Preferred Stock will be limited by the Blocker.

Item 4(b)

Percent of Class:

As of the date hereof, the Reporting Person may be deemed the beneficial owner of approximately 7.4% of the shares of Common Stock outstanding. The percentage set forth herein is calculated based on (i) 93,986,470 shares of Common Stock outstanding as of March 25, 2022, as reported in the Issuer’s definitive proxy statement on Schedule 14A, filed on April 8, 2022, and (ii) the 7,500,000 shares of Common Stock that the Reporting Person currently has the right to acquire upon conversion of the Series X Preferred Stock.

Item 4(c)

Number of Shares as to which such person has:

(i) Sole power to vote or direct the vote: 7,500,000*

(ii) Shared power to vote or direct the vote: 0

(iii) Sole power to dispose or direct the disposition of: 7,500,000*

(iv) Shared power to dispose or direct the disposition of: 0

Item 5

Ownership of Five Percent or Less of a Class

Not Applicable.

Item 6

Ownership of More than Five Percent on Behalf of Another Person

Not Applicable.

Item 7

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

Not Applicable.

Item 8

Identification and Classification of Members of the Group

Not Applicable.

SCHEDULE 13G

CUSIP: 774374102 Page 5 of 6 Pages

Item 9

Notice of Dissolution of Group

Not Applicable.

Item 10

Certification

Not Applicable.

SCHEDULE 13G

CUSIP: 774374102 Page 6 of 6 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: April 18, 2022

DAVITA INC.

By:

/s/ Stephanie N. Berberich

Name:

Stephanie N. Berberich

Title:

Assistant Secretary

SEC Form SC 13G filed by Rockwell Medical Inc. (DE)